Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

WESTLAKE VILLAGE, Calif., July 28, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date.